Adma Biologics (ADMA) EBITDA (2011 - 2026)
Adma Biologics' (ADMA) quarterly EBITDA came in at $62.8 million in Q4 2025, up 63.74% YoY from $38.3 million in Q4 2024, and up 23.01% on a QoQ basis from $51.0 million in Q3 2025.
Adma Biologics (ADMA) EBITDA (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of EBITDA data on file, last reported at $62.8 million in Q4 2025.
- Quarterly EBITDA rose 63.74% year-over-year to $62.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $191.4 million (up 37.74% YoY) and the FY2025 annual result came in at $191.4 million, up 37.75% from the prior year.
- EBITDA grew to $62.8 million in Q4 2025, from $51.0 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $62.8 million in Q4 2025 to a low of -$15.6 million in Q2 2021.
- A 5-year average of $12.7 million and a median of $4.1 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2021 — EBITDA slipped 4.61% — and 2024, when it surged 8387.74%.
- Tracing ADMA's EBITDA over 5 years: stood at -$13.2 million in 2021, then soared by 54.07% to -$6.1 million in 2022, then surged by 334.93% to $14.2 million in 2023, then jumped by 169.25% to $38.3 million in 2024, then jumped by 63.74% to $62.8 million in 2025.
- The last three EBITDA figures came in at $62.8 million (Q4 2025), $51.0 million (Q3 2025), and $42.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 52.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.45 Mn |
| Dec 31, 2025 | 62.75 Mn |
| Sep 30, 2025 | 51.01 Mn |
| Jun 30, 2025 | 42.80 Mn |
| Mar 31, 2025 | 34.88 Mn |
| Dec 31, 2024 | 38.32 Mn |
| Sep 30, 2024 | 39.64 Mn |
| Jun 30, 2024 | 39.20 Mn |
| Mar 31, 2024 | 21.82 Mn |
| Dec 31, 2023 | 14.23 Mn |
| Sep 30, 2023 | 8.69 Mn |
| Jun 30, 2023 | -473,000.00 |
| Mar 31, 2023 | -813,000.00 |
| Dec 31, 2022 | -6.06 Mn |
| Sep 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -9.17 Mn |
| Mar 31, 2022 | -14.82 Mn |
| Dec 31, 2021 | -13.19 Mn |
| Sep 30, 2021 | -14.44 Mn |
| Jun 30, 2021 | -15.58 Mn |